ZyVersa Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $21.65 Mil.
During the past 12 months, ZyVersa Therapeutics's average Total Assets Growth Rate was -82.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 233.60% per year.
During the past 4 years, ZyVersa Therapeutics's highest 3-Year average Total Assets Growth Rate was 233.60%. The lowest was 233.60%. And the median was 233.60%.
The historical data trend for ZyVersa Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
ZyVersa Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZyVersa Therapeutics (NAS:ZVSA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
ZyVersa Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
ZyVersa Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of ZyVersa Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVSA has been successfully added to your 